tirzepatide regulatory filings WHO adds GLP-1RAs to essential medicines list This is very interesting news.

Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them particularly once market competition makes these drugs more accessible

Orforglipron (and elecoglipron) are different, non-peptide "small-molecule" pills with no food or water rules, still at the trial or early-approval stage

Timing the GLP-1 injection appropriately relative to oral medications is a practical consideration

Retinopatia diabetica Nei pazienti diabetici, un rapido miglioramento del controllo glicemico pu temporaneamente peggiorare i sintomi della retinopatia

Dose-response curves show that protein synthesis rates plateau around 80 mcg/day in most mammalian models

Maybe it helps